SLC5A2 and diabetic ketoacidosis: While the results of meta-analyses comparing the rates of AKI remain inconclusive, a recent study by Kuo et al. demonstrated that, among 82,654 cancer patients undergoing chemotherapy with anthracyclines, SGLT2 inhibitor use (n = 19,831) was associated with a lower risk of sepsis and no increased risk of diabetic ketoacidosis [76,85].